Literature DB >> 15015709

Population pharmacokinetics of imipenem in burn patients.

Eric Dailly1, Marie France Kergueris, Michel Pannier, Pascale Jolliet, Michel Bourin.   

Abstract

The interindividual variability of imipenem pharmacokinetic parameters in burn patients suggest that these parameters have to be estimated with a large number of patients. The aim of this study is (i) to estimate these parameters with a population pharmacokinetic approach, and (ii) to test the influence of factors on pharmacokinetics parameters. Data are provided by therapeutic drug monitoring (n = 47,118 samples) and analysed by a nonlinear mixed effect modelling method. Among the tested covariates (age, gender, body weight, height, size of burn and creatinine plasma level) creatinine plasma level affects imipenem pharmacokinetic parameters substantially. The best fit is obtained with a two-compartment model integrating a linear-inverse relationship between imipenem clearance and creatinine plasma level. The estimates of imipenem clearance (16.37 +/- 0.204 L/h) and of the distribution volume of the central compartment (0.376 +/- 0.039 L/kg) are higher in the population of burn patients than the estimates in healthy subjects. This result is connected with high values of glomerule filtration rate and confirms the interest of therapeutic drug monitoring of imipenem in burn patients and particularly for patients with extreme values of creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15015709     DOI: 10.1046/j.1472-8206.2003.00190.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

1.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

2.  Assessment of renal function in clinical practice at the bedside of burn patients.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; M Lavit; K Samii; G Houin; I Tack; S Saivin
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

3.  Penetration of ertapenem into muscle measured by in vivo microdialysis in mechanically ventilated patients.

Authors:  I Boyadjiev; A Boulamery; N Simon; C Martin; B Bruguerolle; M Leone
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

4.  Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.

Authors:  Partha Nandy; Mahesh N Samtani; Rachel Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 5.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.

Authors:  Samir G Sakka; Anna K Glauner; Jürgen B Bulitta; Martina Kinzig-Schippers; Wolfgang Pfister; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

7.  Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.

Authors:  David S Gomez; Cristina Sanches-Giraud; Carlindo V Silva; Amanda M Ribas Rosa Oliveira; Joao Manoel da Silva; Rolf Gemperli; Silvia R C J Santos
Journal:  J Antibiot (Tokyo)       Date:  2014-09-17       Impact factor: 2.649

8.  Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System.

Authors:  Elaine D Por; Kevin S Akers; Kevin K Chung; Jeffrey R Livezey; Daniel J Selig
Journal:  J Clin Pharmacol       Date:  2021-06-19       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.